Key result
Nisoldipine ER reduced 24-h blood pressure by -23/-16 mm Hg compared to -20/-15 mm Hg with amlodipine in African American patients with hypertension.
Why the study?
Does nisoldipine extended-release reduce ambulatory blood pressure as effectively as amlodipine in African American patients with hypertension?
RCT (n=192)
double-blind
randomized
Does nisoldipine extended-release reduce ambulatory blood pressure as effectively as amlodipine in African American patients with hypertension?
Nisoldipine extended-release is as effective as amlodipine in reducing 24-hour ambulatory blood pressure in African American patients with hypertension, with a similar safety profile.
Answers are grounded in this paper and cite their sources.
Supports nisoldipine ER as an equivalent option to amlodipine for 24-h BP control in African American patients; extends randomized evidence for CCB selection in this group.
BACKGROUND: This study evaluates the efficacy of the new dihydropyridine calcium antagonist nisoldipine extended-release (ER) compared to amlodipine on ambulatory and clinic blood pressures (BP) and heart rates in African American patients with hypertension. METHODS: This prospective, double-blind trial randomized 192 patients with office diastolic BP of 95 to 114 mm Hg to receive either nisoldipine (20 to 60 mg once daily) or amlodipine (5 to 10 mg once daily) for 12 weeks in a titration-to-effect design. Using ambulatory monitoring, efficacy was assessed by measuring change from baseline in systolic and diastolic BP and heart rate during three time intervals: 24-h mean period, awake, and sleep. In addition, a subanalysis was performed to evaluate patients whose nocturnal decline in BP was elevated (nondippers) versus those whose BP declined by 10% or more (dippers). RESULTS: Substantial and significant mean changes from baseline in 24-h BP were observed for patients treated with nisoldipine ER (-23/-16 +/- 3/2 mm Hg) and amlodipine (-20/15 +/- 3/2 mm Hg) (between-group comparisons, P =.07 for systolic BP; P =.50 for diastolic BP). Significant and similar reductions also were observed for clinic, awake, and sleep BP. Reductions in BP in the nondippers was substantially greater than in patients with a dipper profile. Neither agent had a significant effect on ambulatory heart rate. Adverse events were mild and infrequent (headache, edema, and dizziness at rates of 4% to 15%), and similar for both agents. CONCLUSIONS: Nisoldipine ER was as effective as amlodipine in reducing 24-h BP in African-American patients with hypertension, with a similar adverse effect profile. Thus, this new therapy for delivery of a dihydropyridine calcium channel blocker is a useful antihypertensive strategy for African-American patients with hypertension.
No takes yet. Share an insight, caveat, or question.
William B. White (2003) conducted an RCT in hypertension (n=192). nisoldipine extended-release (ER) vs. amlodipine (5 to 10 mg once daily) was evaluated on change from baseline in 24-h mean systolic and diastolic BP (p=P =.07 for systolic BP; P =.50 for diastolic BP). Nisoldipine ER reduced 24-h blood pressure by -23/-16 mm Hg compared to -20/-15 mm Hg with amlodipine in African American patients with hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: